Nearly three years after the start of the COVID-19 pandemic, the critical importance of investing in biomedical research and development (R&D) to achieve Health for All has become more apparent than ever. New, effective vaccines were developed with unprecedented speed thanks to a level of global investment and collaboration in R&D that matched the urgency of the crisis. However, these remarkable efforts also exposed serious gaps in equitable access to health tools, technologies, and services, which have had a negative impact on key areas of development. The lesson is clear: investing in both biomedical innovation and equitable access is necessary to achieve Health for All, which in turn is a driver for sustainable development. Join us for an interactive discussion on how good practices in innovation are contributing to the achievement of the third Sustainable Development Goal, and the solutions needed to support sustainable and expanded scientific collaborations. The session will end with a Q&A.

Register on the event website. 

This event is co-organized by Drugs for Neglected Diseases initiative, Medicines for Malaria Venture, and TB Alliance.